The organoid technology is a fast-emerging pre-clinical model system. Organoids closely resemble the organ they were derived from and can be obtained with high efficiency from patient-derived healthy and diseased tissue, which opens opportunities for the development of individualized therapies. Embedded within the
Drost group, the organoid facility supports organoid-based projects by facilitating quality-tested conditioned media, growth factors and know-how.
